Concerted action of IFN-α and IFN-γ induces local NK cell immunity and halts cancer growth

Oncotarget

Volumn 7, Issue 31, 2016, Pages 49259-49267

  Lasfar, Ahmed ^a,b   de la Torre, Andrew ^c,d   Abushahba, Walid ^e   Cohen Solal, Karine A ^b,f   Castaneda, Ismael ^c   Yuan, Yao ^g   Reuhl, Kenneth ^a,b   Zloza, Andrew ^b,f   Raveche, Elizabeth ^b,g   Laskin, Debra L ^a,b   Kotenko, Sergei V ^e  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d ST JOSEPH S REGIONAL MEDICAL CENTER   (United States)

^e Rutgers The State University of New Jersey   (United States)

^f ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

HCV; Hepatocellular carcinoma; IFN therapy; IFN IFN combination; Tumor immunity

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON DERIVATIVE; ANTINEOPLASTIC AGENT; INTERFERON; INTERFERON LAMBDA; UNCLASSIFIED DRUG; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURGERY; CELL ACTIVITY; CELL COUNT; CELL INFILTRATION; CELLULAR IMMUNITY; COMBINATION DRUG THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LOW DRUG DOSE; MONOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; FLOW CYTOMETRY; GENE THERAPY; IMMUNOLOGY; IMMUNOTHERAPY; LIVER TUMOR; METABOLISM; MONONUCLEAR CELL;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; GENETIC THERAPY; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C;

EID: 84981343996     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10272     Document Type: Article

References (38)

1. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Seminars in liver disease. 2010; 30:3-16.
2. Georgiades C, Geschwind JF, Harrison N, Hines-Peralta A, Liapi E, Hong K, Wu Z, Kamel I, Frangakis C. Lack of Response after Initial Chemoembolization for Hepatocellular Carcinoma: Does It Predict Failure of Subsequent Treatment? Radiology. 2012.
3. Melloul E, Lesurtel M, Carr BI, Clavien PA. Developments in liver transplantation for hepatocellular carcinoma. Seminars in oncology. 2012; 39:510-521.
4. Shimomura S, Ikeda N, Saito M, Ishii A, Takashima T, Sakai Y, Yoshikawa S, Aizawa N, Tanaka H, Iwata Y, Enomoto H, Imanishi H, Yamamoto T, et al. Long-term interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinoma. Hepatol Int. 2010; 5:559-566.
5. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, Liaw YF. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007; 46:45-52.
6. Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, Sheen IS, Chang WY, Lee CM, Liaw YF. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther. 2006; 11:985-994.
7. Ishikawa T. Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients. World journal of gastroenterology. 2008; 14:6140-6144.
8. Ishikawa T, Higuchi K, Kubota T, Seki K, Honma T, Yoshida T, Kamimura T. Combination PEG-IFN a-2b/Ribavirin Therapy Following Treatment of Hepatitis C Virus-Associated Hepatocellular Carcinoma is Capable of Improving Hepatic Functional Reserve and Survival. Hepato-gastroenterology. 2012; 59:529-532.
9. Abushahba W, Balan M, Castaneda I, Yuan Y, Reuhl K, Raveche E, de la Torre A, Lasfar A, Kotenko SV. Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother. 2010; 59:1059-1071.
10. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. The oncologist. 2001; 6:34-55.
11. Pestka S, Krause CD, Walter MR. Interferons, interferonlike cytokines, and their receptors. Immunol Rev. 2004; 202:8-32.
12. Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, Tian B, Reuhl K, Dickensheets H, Sheikh F, Donnelly RP, Raveche E, Kotenko SV. Characterization of the mouse IFN-lambda ligand-receptor system: IFNlambdas exhibit antitumor activity against B16 melanoma. Cancer research. 2006; 66:4468-4477.
13. Willemen Y, Van den Bergh JM, Lion E, Anguille S, Roelandts VA, Van Acker HH, Heynderickx SD, Stein BM, Peeters M, Figdor CG, Van Tendeloo VF, de Vries IJ, Adema GJ, et al. Engineering monocyte-derived dendritic cells to secrete interferon-alpha enhances their ability to promote adaptive and innate anti-tumor immune effector functions. Cancer Immunol Immunother. 2015; 64:831-842.
14. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T. Antitumor activity of IFN-lambda in murine tumor models. J Immunol. 2006; 176:7686-7694.
15. Souza-Fonseca-Guimaraes F, Young A, Mittal D, Martinet L, Bruedigam C, Takeda K, Andoniou CE, Degli-Esposti MA, Hill GR and Smyth MJ. NK cells require IL-28R for optimal in vivo activity. Proc Natl Acad Sci U S A 2015.
16. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015; 15:405-414.
17. de Groen RA, Boltjes A, Hou J, Liu BS, McPhee F, Friborg J, Janssen HL, Boonstra A. IFN-lambda-mediated IL-12 production in macrophages induces IFN-gamma production in human NK cells. Eur J Immunol. 2015; 45:250-259.
18. Morrison MH, Keane C, Quinn LM, Kelly A, O'Farrelly C, Bergin C, Gardiner CM. IFNL cytokines do not modulate human or murine NK cell functions. Hum Immunol. 2014; 75:996-1000.
19. Langers I, Renoux VM, Thiry M, Delvenne P, Jacobs N. Natural killer cells: role in local tumor growth and metastasis. Biologics: targets & therapy. 2012; 6:73-82.
20. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008; 9:495-502.
21. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science. 2011; 331:44-49.
22. Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Pulido J, Pavelko K, Pease L, Melcher A, Vile R. Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer research. 2010; 70:4539-4549.
23. Nishida S, Levi DM, Tzakis AG. Liver natural killer cell inoculum for liver transplantation with hepatocellular carcinoma. Curr Opin Organ Transplant. 2013; 18:690-694.
24. Ohira M, Nishida S, Tryphonopoulos P, Tekin A, Selvaggi G, Moon J, Levi D, Ricordi C, Ishiyama K, Tanaka Y, Ohdan H, Tzakis AG. Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma. Cell Transplant. 2012; 21:1397-1406.
25. Childs RW, Carlsten M. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nat Rev Drug Discov. 2015; 14:487-498.
26. Ahn J, Xia T, Konno H, Konno K, Ruiz P, Barber GN. Inflammation-driven carcinogenesis is mediated through STING. Nat Commun. 2014; 5:5166.
27. Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber GN, Fitzgerald KA, Alegre ML, Gajewski TF. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014; 41:830-842.
28. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41:1100-1104.
29. McFarland AP, Horner SM, Jarret A, Joslyn RC, Bindewald E, Shapiro BA, Delker DA, Hagedorn CH, Carrington M, Gale M Jr, Savan R. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol. 2014; 15:72-79.
30. Terczynska-Dyla E, Bibert S, Duong FH, Krol I, Jorgensen S, Collinet E, Kutalik Z, Aubert V, Cerny A, Kaiser L, Malinverni R, Mangia A, Moradpour D, et al. Reduced IFNlambda4 activity is associated with improved HCV clearance and reduced expression of interferonstimulated genes. Nat Commun. 2014; 5:5699.
31. Duong FH, Trincucci G, Boldanova T, Calabrese D, Campana B, Krol I, Durand SC, Heydmann L, Zeisel MB, Baumert TF, Heim MH. IFN-lambda receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-lambda3 genotype and with nonresponsiveness to IFNalpha therapies. J Exp Med. 2014; 211:857-868.
32. Golden-Mason L, Bambha KM, Cheng L, Howell CD, Taylor MW, Clark PJ, Afdhal N, Rosen HR. Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. Hepatology. 2011; 54:1559-1569.
33. Meng Q, Rani MR, Sugalski JM, Judge CJ, Phat S, Rodriguez B, Blanton RE, Anthony DD. Natural cytotoxicity receptor-dependent natural killer cytolytic activity directed at hepatitis C Virus (HCV) is associated with liver inflammation, African American race, IL28B genotype, and response to pegylated interferon/ribavirin therapy in chronic HCV infection. J Infect Dis. 2014; 209:1591-1601.
34. Burkart C, Arimoto K, Tang T, Cong X, Xiao N, Liu YC, Kotenko SV, Ellies LG, Zhang DE. Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-lambda and elevated secretion of Cxcl10. EMBO Mol Med. 2013; 5:967-982.
35. Francois-Newton V, Magno de Freitas Almeida G, Payelle-Brogard B, Monneron D, Pichard-Garcia L, Piehler J, Pellegrini S, Uze G. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response. PloS one. 2011; 6:e22200.
36. Makowska Z, Duong FH, Trincucci G, Tough DF Heim MH. Interferon-beta and interferon-lambda signaling is not affected by interferon-induced refractoriness to interferon-alpha in vivo. Hepatology. 2011; 53:1154-1163.
37. Fujie H, Tanaka T, Tagawa M, Kaijun N, Watanabe M, Suzuki T, Nakayama K, Numasaki M. Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer. Cancer Sci. 2011; 102:1977-1990.
38. Stiff A, Carson Iii W. Investigations of interferon-lambda for the treatment of cancer. J Innate Immun. 2015; 7:243-250.